Muscular Dystrophy Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Muscular Dystrophy stocks.

Muscular Dystrophy Stocks Recent News

Date Stock Title
May 16 TRDA Director Peter Kim Acquires 25,000 Shares of Entrada Therapeutics Inc (TRDA)
May 16 BNTC Benitec Biopharma files to sell 32.87M shares of common stock for holders
May 16 TRDA Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
May 15 WVE Wells Fargo starts Wave Life Sciences at buy, cites valuation
May 14 PTCT PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts
May 14 SRPT Sarepta upgraded at Oppenheimer on potential Elevidys label expansion
May 14 PTCT PTC Therapeutics wins FDA priority review for gene therapy
May 14 PTCT PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstazaâ„¢
May 13 BNTC Benitec GAAP EPS of -$1.64
May 13 BOLD Boundless Bio GAAP EPS of -$12.27 misses by $11.54
May 13 BNTC Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update
May 13 BOLD Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights
May 12 WVE Wave Life Sciences Ltd. (NASDAQ:WVE) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
May 10 WVE Wave Life Sciences Ltd. (NASDAQ:WVE) Q1 2024 Earnings Call Transcript
May 10 WVE WAVE Life Sciences Reports First Quarter 2024 Financial Results
May 10 EWTX Edgewise: Intriguing Drug Candidate, But Consider Selling After Recent Run
May 10 EWTX Edgewise Therapeutics Inc (EWTX) Reports First Quarter 2024 Financial Results
May 10 EWTX Edgewise Therapeutics files mixed securities shelf
May 10 WVE Wave Life Sciences First Quarter 2024 Earnings: US$0.24 loss per share (vs US$0.27 loss in 1Q 2023)
May 10 EWTX Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024
Muscular Dystrophy

Muscular dystrophy (MD) is a group of muscle diseases that results in increasing weakening and breakdown of skeletal muscles over time. The disorders differ in which muscles are primarily affected, the degree of weakness, how fast they worsen, and when symptoms begin. Many people will eventually become unable to walk. Some types are also associated with problems in other organs.The muscular dystrophy group contains thirty different genetic disorders that are usually classified into nine main categories or types. The most common type is Duchenne muscular dystrophy (DMD) which typically affects males beginning around the age of four. Other types include Becker muscular dystrophy, facioscapulohumeral muscular dystrophy, and myotonic dystrophy. They are due to mutations in genes that are involved in making muscle proteins. This can occur due to either inheriting the defect from one's parents or the mutation occurring during early development. Disorders may be X-linked recessive, autosomal recessive, or autosomal dominant. Diagnosis often involves blood tests and genetic testing.There is no cure for muscular dystrophy. Physical therapy, braces, and corrective surgery may help with some symptoms. Assisted ventilation may be required in those with weakness of breathing muscles. Medications used include steroids to slow muscle degeneration, anticonvulsants to control seizures and some muscle activity, and immunosuppressants to delay damage to dying muscle cells. Outcomes depend on the specific type of disorder.Duchenne muscular dystrophy, which represents about half of all cases of muscular dystrophy, affects about one in 5,000 males at birth. Muscular dystrophy was first described in the 1830s by Charles Bell. The word "dystrophy" is from the Greek dys, meaning "difficult" and troph meaning "nourish". Gene therapy, as a treatment, is in the early stages of study in humans.

Browse All Tags